Mannheimia haemolytica leukotoxin binds to lipid rafts in bovine lymphoblastoid cells and is internalized in a dynamin-2- and clathrin-dependent manner.

Department of Pathobiological Sciences, University of Wisconsin, 2015, Linden Drive, West, Madison, WI 53706, USA.
Infection and Immunity (Impact Factor: 4.16). 11/2007; 75(10):4719-27. DOI: 10.1128/IAI.00534-07
Source: PubMed

ABSTRACT Mannheimia haemolytica is the principal bacterial pathogen of the bovine respiratory disease complex. Its most important virulence factor is a leukotoxin (LKT), which is a member of the RTX family of exotoxins produced by many gram-negative bacteria. Previous studies demonstrated that LKT binds to the beta(2)-integrin LFA-1 (CD11a/CD18) on bovine leukocytes, resulting in cell death. In this study, we demonstrated that depletion of lipid rafts significantly decreases LKT-induced bovine lymphoblastoid cell (BL-3) death. After binding to BL-3 cells, some of the LKT relocated to lipid rafts in an LFA-1-independent manner. We hypothesized that after binding to LFA-1 on BL-3 cells, LKT moves to lipid rafts and clathrin-coated pits via a dynamic process that results in LKT internalization and cytotoxicity. Knocking down dynamin-2 by small interfering RNA reduced both LKT internalization and cytotoxicity. Similarly, expression of dominant negative Eps15 protein expression, which is required for clathrin coat formation, reduced LKT internalization and LKT-mediated cytotoxicity to BL-3 cells. Finally, we demonstrated that inhibiting actin polymerization reduced both LKT internalization and LKT-mediated cytotoxicity. These results suggest that both lipid rafts and clathrin-mediated mechanisms are important for LKT internalization and cytotoxicity in BL-3 cells and illustrate the complex nature of LKT internalization by the cytoskeletal network.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bacterial pneumonia is a common and often life-threatening respiratory problem in both meat and dairy goats. Options for approved antibiotic therapy in goats to combat these bacterial infections are severely limited and frequently drugs must be used in an extra-label manner. Tulathromycin, a triamilide macrolide antimicrobial drug shown to be effective against swine and cattle respiratory bacterial agents, has been identified as a potentially useful drug in caprines. The present study was conducted to determine the susceptibility of recognized bacterial respiratory pathogens to commonly prescribed antimicrobials, with a particular emphasis on the efficacy of tulathromycin against these agents. Minimum inhibitory concentration (MIC) testing using microbroth dilution was performed on a collection of 45 Mannheimia haemolytica, 11 Pasteurella multocida, and 11 Bibersteinia trehalosi isolates from the lungs of goats with clinical pneumonia. To further characterize efficacy of tulathromycin against these pathogens, minimum bactericidal concentration (MBC) testing and kinetic killing assays were conducted. Most isolates were susceptible to the antimicrobials tested; however, increased resistance as demonstrated by higher MIC values was seen in all species to penicillin, in P. multocida to sulfadimethoxine, and in B. trehalosi to the tetracyclines. All isolates were susceptible to tulathromycin, which demonstrated a high killing efficiency in both bactericidal assays. Results of this study indicate that most goat pneumonic bacterial pathogens remain susceptible to commonly prescribed antibiotics, although some evidence of resistance was seen to certain drugs; and that tulathromycin is highly effective against goat respiratory pathogens which could make it a valuable medication in this species.
    Veterinary Microbiology 10/2011; 156(1-2):178-82. DOI:10.1016/j.vetmic.2011.10.025 · 2.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The number of antimicrobials available to treat bacterial respiratory disease in goats is extremely limited. Currently, only ceftiofur has been approved for use in this species. Concerns over the development of antimicrobial resistance in bacteria that infect humans have led to proposed restrictions on the use of this drug in food-producing animals. Tulathromycin, a triamilide macrolide antibiotic found to be safe and effective against respiratory bacterial pathogens in cattle and swine, was formulated to enhance persistence in lung tissue. The Minor Use Animal Drug Program (National Research Support Project-7) identifies and supports research directed at meeting the Food and Drug Administration (FDA) requirements for drug approval in minor species or for minor uses in major species. The current work was undertaken to support FDA approval of tulathromycin in the caprine species by providing an assessment of target animal drug safety, drug tissue elimination, and drug efficacy. Tulathromycin had no detrimental clinical effects, even in animals treated with 5X the proposed label dose for three times the proposed label duration. Tissue elimination and pharmacokinetic behavior paralleled that found in both cattle and swine. Efficacy analysis was conducted on the clinical effect and pharmacokinetic behavior of tulathromycin in goats as well as in vitro antimicrobial effects on bacterial isolates recovered from goats. Bacteria isolated from goats with clinical cases of pneumonia were highly susceptible to this drug in several in vitro assays. Overall, this research demonstrated that tulathromycin would be a safe, effective, and valuable medication in the treatment of bacterial pneumonia in goats.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mannheimia haemolytica is an important member of the bovine respiratory disease (BRD) complex that causes fibrinous and necrotizing pleuropneumonia in cattle. BRD is characterized by abundant neutrophil infiltration into the alveoli and fibrin deposition. The most important virulence factor of M. haemolytica is its leukotoxin. Previous research in our laboratory has shown that the leukotoxin is able to enter into and traffic to the mitochondria of a bovine lymphoblastoid cell line (BL-3). In this study, we evaluated the ability of LKT to be internalized and travel to mitochondria in bovine neutrophils. We demonstrate that LKT binds bovine neutrophil mitochondria and co-immunoprecipitates with TOM22 and TOM40, which are members of the translocase of the outer mitochondrial (TOM) membrane family. Upon entry into mitochondria, LKT co-immunoprecipitates with cyclophilin D, a member of the mitochondria permeability transition pore. Unlike BL-3 cells, bovine neutrophil mitochondria are not protected against LKT by the membrane-stabilizing agent cyclosporin A, nor were bovine neutrophil mitochondria protected by the permeability transition pore antagonist bongkrekic acid. In addition, we found that bovine neutrophil cyclophilin D is significantly smaller than that found in BL-3 cells. Bovine neutrophils were protected against LKT by protein transfection of an anti-cyclophilin D antibody directed at the C-terminal amino acids, but not an antibody against the first 50 N-terminal amino acids. In contrast, BL-3 cells were protected by antibodies against either the C-terminus or N-terminus of cyclophilin. These data confirm that LKT binds to bovine neutrophil mitochondria, but indicate there are distinctions between neutrophil and BL-3 mitochondria that might reflect differences in cyclophilin D.
    Microbial Pathogenesis 03/2011; 50(3-4):168-78. DOI:10.1016/j.micpath.2011.01.001 · 2.00 Impact Factor


Available from